Business
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
- Closed registered direct offering for aggregate gross proceeds of US$175 million (the “R...
About this update from Cybin, Inc.
[{"type":"text","content":"Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }\n \n\n\n\n\n - Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors -\n \n\n\n\n - On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized Anxiety Disorder (“GAD”) in Q1 2026\n \n 1\n \n -\n \n\n\n\n - Continues to advance Phase 3 studies of CYB003 for the adjunctive treatment of major depressive disorder (“MDD”) -\n \n\n\n\n -The Company’s cash position as at September 30, 2025 after giving effect to the net proceeds of the Registered Direct Offering is US$248 million -\n \n\n\n -\n \n Repayment of outstanding convertible debentures to High Trail Special Situations LLC and debt retired in full\n \n -\n \n\n -\n \n Company to host conference call and webcast at 8:00 a.m. ET today\n \n -\n \n\n\n\n\n Cybin Inc.\n \n (NYSE American:CYBN) (Cboe CA:CYBN) (“\n \n Cybin\n \n ” or the “\n \n Company\n \n ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported unaudited financial results for its second quarter ended September 30, 2025, and recent business highlights.\n \n\n “We are extremely pleased with the strong demand for our recently completed financing,” said Eric So, Interim Chief Executive Officer of Cybin. “The participation of notable institutional investors underscores confidence in the strength of our science, the potential and differentiation of our therapeutic candidates, and our team’s proven ability to execute. This financing enables us to maintain strong momentum as we advance our Phase 2 and Phase 3 clinical trials toward key data readouts in 2026 and work to deliver meaningful clinical outcomes and potentially transformative therapies closer to patients in need.”\n \n\n “Across the organization we are focused on a disciplined execution strategy and b...